Evidence map›Paper›PMID 35538945›Full record

ArticleRSC advances2018

Gold nanocolloid-protein interactions and their impact on β-sheet amyloid fibril formation.

Heloise R Barros, Maria Kokkinopoulou, Izabel C Riegel-Vidotti, Katharina Landfester, Héloïse Thérien-Aubin

Open access · goldAbstract read
In one paragraph

Article in RSC advances, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Heloise R BarrosMax Planck Institute for Polymer Research 55128 Mainz Germany therien@mpip-mainz.mpg.de.
Maria KokkinopoulouMax Planck Institute for Polymer Research 55128 Mainz Germany therien@mpip-mainz.mpg.de.
Izabel C Riegel-VidottiDepartamento de Química, Universidade Federal do Paraná CxP 19081, CEP 81531-980 Curitiba PR Brazil.ORCID https://orcid.org/0000-0002-7649-8947
Katharina LandfesterMax Planck Institute for Polymer Research 55128 Mainz Germany therien@mpip-mainz.mpg.de.ORCID https://orcid.org/0000-0001-9591-4638
Héloïse Thérien-AubinMax Planck Institute for Polymer Research 55128 Mainz Germany therien@mpip-mainz.mpg.de.ORCID https://orcid.org/0000-0003-4567-516X
University of Applied Sciences Mainz · DECentro Universitário Curitiba · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The influence of the presence of small molecules and nanoparticles on the mechanism of amyloid fibril formation has attracted attention because amyloid protein fibrils are associated with degenerative diseases. Here, we studied the interaction between gold nanoparticles (AuNPs) and a model protein (lysozyme). Both the formation of amyloid fibrils in the presence of gold nanoparticles, as well as the interaction between lysozyme and the amyloid fibrils with AuNPs, were investigated to gain an understanding of the distinct behaviour of lysozyme in its fibrillar and globular form. It was observed that the presence of AuNPs delayed the unfolding of α-helixes present in the globular lysozyme and the formation of the amyloid fibrils. However, the addition of AuNPs was also associated with a larger amount of β-sheet structures in the system once equilibrium was reached. Furthermore, the results showed that the driving force of the interaction between AuNPs and lysozyme in its fibrillar and globular forms was significantly different, and that the interaction of AuNPs with the preformed lysozyme amyloid fibrils led to a structural change in the protein.

Identifiers

PMID35538945
PMCPMC9077019
OpenAlexW2781802889

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.